Bristol-Myers Squibb Company (BMY)
NYSE: BMY · Real-Time Price · USD
61.35
-1.58 (-2.51%)
At close: Nov 17, 2026, 4:00 PM EST
61.00
-0.35 (-0.57%)
Pre-market: Nov 18, 2026, 6:06 AM EST
BMY Revenue
Bristol-Myers Squibb Company had revenue of $13.07B in the quarter ending September 30, 2026, with 6.93% growth. This brings the company's total for the last twelve months to $50.03B, up 4.16% year-over-year. In the year 2025, Bristol-Myers Squibb Company had annual revenue of $48.19B, down -0.22%. That makes Bristol-Myers Squibb Company the 257th largest company in the world by revenue and 98th in the United States.
Revenue (ttm)
$50.03B
Revenue Growth
+4.16%
P/S Ratio
2.51
Revenue / Employee
$1,539,477
Employees
32,500
Market Cap
125.40B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full BMY breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 48.19B | -106.00M | -0.22% |
| Dec 31, 2024 | 48.30B | 3.29B | 7.32% |
| Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
| Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
| Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
| Dec 31, 2020 | 42.52B | 16.37B | 62.62% |
| Dec 31, 2019 | 26.15B | 3.58B | 15.89% |
| Dec 31, 2018 | 22.56B | 1.79B | 8.59% |
| Dec 31, 2017 | 20.78B | 1.35B | 6.94% |
| Dec 31, 2016 | 19.43B | 2.87B | 17.31% |
| Dec 31, 2015 | 16.56B | 681.00M | 4.29% |
| Dec 31, 2014 | 15.88B | -506.00M | -3.09% |
| Dec 31, 2013 | 16.39B | -1.24B | -7.01% |
| Dec 31, 2012 | 17.62B | -3.62B | -17.05% |
| Dec 31, 2011 | 21.24B | 1.76B | 9.03% |
| Dec 31, 2010 | 19.48B | 676.00M | 3.59% |
| Dec 31, 2009 | 18.81B | 1.09B | 6.17% |
| Dec 31, 2008 | 17.72B | 2.10B | 13.43% |
| Dec 31, 2007 | 15.62B | -591.00M | -3.65% |
| Dec 31, 2006 | 16.21B | -2.40B | -12.88% |
| Dec 31, 2005 | 18.61B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Merck & Co. | 67.38B |
| AbbVie | 66.01B |
| Pfizer | 63.62B |
| AstraZeneca | 62.38B |
| Sanofi | 57.89B |
| Novartis AG | 57.36B |
| Novo Nordisk | 50.70B |
| GSK plc | 44.53B |
BMY News
- 11 hours ago - Erasca announces agreement with Bristol Myers - TheFly
- 19 hours ago - Bristol Myers Squibb put volume heavy and directionally bearish - TheFly
- 4 days ago - 14 dividend stocks selected for long-term growth - Market Watch
- 5 days ago - Bristol Myers to merge scientific, clinical teams under new R&D structure - Reuters
- 5 days ago - Bristol Myers Squibb Announces Evolution of Research & Development Organization - Business Wire
- 6 days ago - Our Bristol Myers Squibb Stock Pick Is Up 35%. It's Still a Good Bet in Healthcare. - Barrons
- 11 days ago - Bristol Myers presents 56-week data from Phase 3 SCOUT-HCM clinical trial - TheFly
- 11 days ago - Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions - Business Wire